Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,285.28 +7.77 (+0.15%) Dow
38,584.27 -102.05 (-0.26%) Nasdaq
16,839.89 +104.87 (+0.63%) Bitcoin USD
69,257.32 +978.75 (+1.43%) CMC Crypto 200
1,498.89 +30.95 (+2.11%)
MNKD Jan 2025 10.000 call
| Previous close | 0.0800 |
| Open | 0.0800 |
| Bid | 0.0000 |
| Ask | 0.2000 |
| Strike | 10.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0800 - 0.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 4.95k |
PR NewswirePulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary diseases using its patented dry powder inhalation iSPERSE™ technology, today announced a series of transactions with MannKind Corporation (Nasdaq: MNKD).
GlobeNewswireMannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D spaceNon-cash deal includes royalty-free iSPERSE™ technology license in exchange for access to MannKind’s Cricket® inhaler DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and o
ZacksMannKind (MNKD) Upgraded to Strong Buy: Here's Why
MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
